Stock Track | Novo Nordisk Plunges 5.03% on Weak 2026 Outlook Amid Pricing Pressure and Competition

Stock Track02-04 16:59

Novo Nordisk A/S (NVO) experienced a 24-hour plunge of 5.03% during the trading session. The significant decline follows the company's release of a disappointing forecast for the year 2026.

The Danish drugmaker, known for its weight-loss and diabetes medications Wegovy and Ozempic, projected that adjusted sales could fall by 5% to 13% this year, a steeper decline than analysts had anticipated. The company cited several headwinds, including significant pricing pressure stemming from a recent agreement with the U.S. government to lower drug prices for Americans.

Furthermore, Novo Nordisk faces intensifying competition from rivals like Eli Lilly in the lucrative obesity drug market, alongside patent expirations for its key drug ingredient semaglutide in certain international markets. The persistence of compounded, lower-cost copycat versions of its medications in the U.S. also contributes to the challenging outlook, overshadowing a strong initial launch for its new Wegovy pill.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147742694?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 16:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147742694","market":"us","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Plunges 5.03% on Weak 2026 Outlook Amid Pricing Pressure and Competition","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) experienced a 24-hour plunge of 5.03% during the trading session. The significant decline follows the company's release of a disappointing forecast for the year 2026.</p><p>The Danish drugmaker, known for its weight-loss and diabetes medications Wegovy and Ozempic, projected that adjusted sales could fall by 5% to 13% this year, a steeper decline than analysts had anticipated. The company cited several headwinds, including significant pricing pressure stemming from a recent agreement with the U.S. government to lower drug prices for Americans.</p><p>Furthermore, Novo Nordisk faces intensifying competition from rivals like Eli Lilly in the lucrative obesity drug market, alongside patent expirations for its key drug ingredient semaglutide in certain international markets. The persistence of compounded, lower-cost copycat versions of its medications in the U.S. also contributes to the challenging outlook, overshadowing a strong initial launch for its new Wegovy pill.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Plunges 5.03% on Weak 2026 Outlook Amid Pricing Pressure and Competition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Plunges 5.03% on Weak 2026 Outlook Amid Pricing Pressure and Competition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-04 16:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) experienced a 24-hour plunge of 5.03% during the trading session. The significant decline follows the company's release of a disappointing forecast for the year 2026.</p><p>The Danish drugmaker, known for its weight-loss and diabetes medications Wegovy and Ozempic, projected that adjusted sales could fall by 5% to 13% this year, a steeper decline than analysts had anticipated. The company cited several headwinds, including significant pricing pressure stemming from a recent agreement with the U.S. government to lower drug prices for Americans.</p><p>Furthermore, Novo Nordisk faces intensifying competition from rivals like Eli Lilly in the lucrative obesity drug market, alongside patent expirations for its key drug ingredient semaglutide in certain international markets. The persistence of compounded, lower-cost copycat versions of its medications in the U.S. also contributes to the challenging outlook, overshadowing a strong initial launch for its new Wegovy pill.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1147742694","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147742694","pubTimestamp":1770195568,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S (NVO) experienced a 24-hour plunge of 5.03% during the trading session. The significant decline follows the company's release of a disappointing forecast for the year 2026.The Danish...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"个股赛道|定价压力和竞争下诺和诺德2026年前景疲软暴跌5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) experienced a 24-hour plunge of 5.03% during the trading session. The significant decline follows the company's release of a disappointing forecast for the year 2026.The Danish drugmaker, known for its weight-loss and diabetes medications Wegovy and Ozempic, projected that adjusted sales could fall by 5% to 13% this year, a steeper decline than analysts had anticipated. The company cited several headwinds, including significant pricing pressure stemming from a recent agreement with the U.S. government to lower drug prices for Americans.Furthermore, Novo Nordisk faces intensifying competition from rivals like Eli Lilly in the lucrative obesity drug market, alongside patent expirations for its key drug ingredient semaglutide in certain international markets. The persistence of compounded, lower-cost copycat versions of its medications in the U.S. also contributes to the challenging outlook, overshadowing a strong initial launch for its new Wegovy pill.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147742694","isCrawlerRequest":true}